From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

avibactam tomilopil   Click here for help

GtoPdb Ligand ID: 12949

Synonyms: ARX-1796 | AV-006 | PF-07338233
Compound class: Synthetic organic
Comment: Avibactam tomilopil is an orally available prodrug of the β-lactamase inhibitor avibactam [1]. Pfizer are developing an oral combined formulation of avibactam tomilopil and ceftibuten for the treatment of complicated urinary tract infections (cUTIs) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 153.92
Molecular weight 393.41
XLogP -2.46
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC(=O)C(C)(C)COS(=O)(=O)ON1[C@@H]2CC[C@@H](C(=O)N)N(C2)C1=O
Isomeric SMILES CCOC(=O)C(C)(C)COS(=O)(=O)ON1[C@@H]2CC[C@H](N(C2)C1=O)C(=O)N
InChI InChI=1S/C14H23N3O8S/c1-4-23-12(19)14(2,3)8-24-26(21,22)25-17-9-5-6-10(11(15)18)16(7-9)13(17)20/h9-10H,4-8H2,1-3H3,(H2,15,18)/t9-,10+/m1/s1
InChI Key JHSLCXRZVJOZQZ-ZJUUUORDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Avibactam tomilopil in combination with ceftibuten is in early clinical development (Phase 1 trial, NCT05554237) as an oral treatment of cUTIs including pyelonephritis [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05554237 A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People. Phase 1 Interventional Pfizer
NCT03931876 A Single Ascending Dose Study of AV-006 in Healthy Subjects Phase 1 Interventional Arixa Pharmaceuticals